Hansa Biopharma provides business update including certain key financials
· Commercial launch and market access efforts in Europe progressing as planned; New multiregional commercialization partnership with Medison in Central Eastern Europe and Israel · First patients enrolled into the pivotal U.S. ConfIdeS study; Agreement established with AskBio to evaluate feasibility of imlifidase as pre-treatment ahead of gene therapy in Pompe disease · Platform strategy: Hansa to explore desensitization treatment in allogeneic hematopoietic stem cell transplantation · Year-end cash position of SEK 889 million; Hansa financed into 2023, as previously guidedLund,